Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.43 |
| ▸ | GRM5 | P41594 | 9/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.40 |
| ▸ | PREP | P48147 | 4/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.37 |
| ▸ | CPT1A | P50416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL19974982 | 1.00 | DPP4 (0.43) | DPP4DPP8DPP9DPP7GRM5 | |
| SCHEMBL19974983 | 0.83 | DPP4 (0.42) | DPP4DPP8DPP9DPP7GRM5 | |
| SCHEMBL15175875 | 0.75 | SPHK2 (0.51) | — | |
| SCHEMBL15176394 | 0.75 | SPHK2 (0.51) | — | |
| SCHEMBL19979747 | 0.74 | DPP4 (0.40) | DPP4DPP8DPP9DPP7GRM5 | |
| SCHEMBL27230170 | 0.74 | EPHX2 (0.47) | DPP4DPP8DPP9DPP7GRM5 | |
| SCHEMBL29176587 | 0.72 | CPT1A (0.47) | GRM5CPT2CPT1A | |
| SCHEMBL29176586 | 0.72 | CPT1A (0.47) | GRM5CPT2CPT1A | |
| SCHEMBL30147179 | 0.72 | HCRTR1 (0.43) | DPP4DPP8DPP9DPP7GRM5 | |
| SCHEMBL5569867 | 0.72 | DPP4 (0.51) | DPP4DPP8DPP9DPP7GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018053302-A1 | MACROCYCLIC COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE ACTIVITY AND USE THEREOF | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2018-03-22 | — | — | WO | disclosed |